StreetInsider.com News Articles

China SXT Pharmaceuticals announces 1-for-150 share consolidation

Fri, 30 Jan 2026 09:01:42 -0500

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) announced a share consolidation that will combine every 150 ordinary shares into one share, effective February 3, 2026.

The pharmaceutical company said its Class A ordinary shares will begin trading on a post-consolidation basis when markets open on February 3. The shares will continue trading on Nasdaq under the symbol "SXTC" with a new CUSIP number G2161P165.

Before the consolidation, 143,693,892 Class A ordinary shares were issued and outstanding. Following the 1-for-150 consolidation, approximately 957,960 Class A ordinary shares will be outstanding. Fractional shares will be rounded up to the next whole share.

All outstanding stock options,

China SXT Pharmaceuticals announces 1-for-150 share consolidation

Fri, 30 Jan 2026 09:01:42 -0500

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) announced a share consolidation that will combine every 150 ordinary shares into one share, effective February 3, 2026.

All outstanding stock options,

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

Fri, 30 Jan 2026 09:00:00 -0500

TAIZHOU, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the “Company” or “SXTC”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-150, effective on February 3, 2026 (the “Share Consolidation”). The Company’s Class A ordinary shares are expected to begin trading on a post-consolidation basis at

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

Fri, 30 Jan 2026 09:00:00 -0500

CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN

Thu, 15 Jan 2026 09:00:00 -0500

TAIZHOU, China, Jan. 15, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (“China SXT” or the “Company”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced as part of its Artificial Intelligence (AI) Insight Initiative to explore the application of Artificial Intelligence (AI) and related digital technologies across the Traditional Chinese Medicine (TCM) raw-material supply chain. This initiative is part of the Company’s long-term plan to

CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN

Thu, 15 Jan 2026 09:00:00 -0500

China SXT Pharmaceuticals closes $10 million registered direct offering

Tue, 13 Jan 2026 17:00:12 -0500

China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) closed a $10 million registered direct offering on January 13, 2026, according to a statement from Univest Securities, LLC, which served as the sole placement agent.

The pharmaceutical company sold 66,666,666 Class A ordinary shares to a single investor at $0.15 per share. The company also offered pre-funded warrants in lieu of shares at the same purchase price, minus an exercise price of $0.001 per share.

China SXT Pharmaceuticals focuses on traditional Chinese medicine pieces, including advanced TCMPs, fine TCMPs, regular TCMPs, and TCM homologous supplements. The company was founded in 2005 and is headquartered in

Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)

Tue, 13 Jan 2026 17:00:00 -0500

New York, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the “Offering”) of approximately $10 million for its client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the “Company” or “China SXT”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”).

Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)

Tue, 13 Jan 2026 17:00:00 -0500

Form 6-K China SXT Pharmaceutical For: Jan 13

Tue, 13 Jan 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260113/25844115.html

Form 6-K China SXT Pharmaceutical For: Jan 13

Tue, 13 Jan 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260113/25844115.html

Form 424B5 China SXT Pharmaceutical

Mon, 12 Jan 2026 10:51:00 -0500

si-local-file:///var/storage/secattach/20260112/25836173.html

Form 424B5 China SXT Pharmaceutical

Mon, 12 Jan 2026 10:51:00 -0500

si-local-file:///var/storage/secattach/20260112/25836173.html

China SXT Pharmaceuticals raises $10 million in registered direct offering

Fri, 09 Jan 2026 14:50:08 -0500

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) entered into an agreement with a single investor for a registered direct offering of 66,666,666 Class A ordinary shares at $0.15 per share, the company announced.

The offering includes an option for pre-funded warrants in lieu of shares at the same purchase price, minus an exercise price of $0.001 per share. The transaction is expected to generate approximately $10 million in gross proceeds and close on or about January 12, 2026, subject to customary closing conditions.

Univest Securities, LLC serves as the sole placement agent for the offering. The registered direct offering operates under a shelf

China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering

Fri, 09 Jan 2026 14:50:00 -0500

TAIZHOU, China, Jan. 09, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive agreement with a single investor for the purchase and sale of an aggregate of 66,666,666 Class A ordinary shares of the company, no par value per share (the “Shares”) (or pre-funded warrants in lieu thereof), at a purchase price of $0.15 per share in a registered direct offering. The purchase price for each pre-funded warrant is identical to the purchase price for each Share, less the exercise price of $0.001 per share.

China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering

Fri, 09 Jan 2026 14:50:00 -0500

China SXT Pharmaceuticals launches AI initiative for TCM optimization

Thu, 08 Jan 2026 09:21:57 -0500

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) announced the launch of a Strategic Artificial Intelligence Insights Initiative to integrate AI-driven analytics into its Traditional Chinese Medicine product portfolio planning and market intelligence processes.

The Taizhou-based company plans to use AI to analyze historical sales data, regional health demand, product performance trends and supply dynamics of TCM raw materials to guide research and development decisions. The initiative aims to identify new product opportunities and enhance commercial potential assessment for the company's Traditional Chinese Medicine Pieces and TCM Homologous Supplements product lines.

As part of the initiative, China SXT plans to develop and operate AI-supported

CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND EXPLORE AI-SUPPORTED CLINIC DEPLOYMENT

Thu, 08 Jan 2026 09:20:00 -0500

TAIZHOU, China, Jan. 08, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced the launch of a Strategic Artificial Intelligence (AI) Insights Initiative. This initiative aims to integrate AI-driven analytics into the Company’s product portfolio planning and market intelligence processes, further strengthening its long-term strategy to evolve into a data-informed and innovation-driven modern

CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND EXPLORE AI-SUPPORTED CLINIC DEPLOYMENT

Thu, 08 Jan 2026 09:20:00 -0500

Form 6-K China SXT Pharmaceutical For: Sep 30

Wed, 31 Dec 2025 16:01:00 -0500

si-local-file:///var/storage/secattach/20251231/25794398.html

Form 6-K China SXT Pharmaceutical For: Sep 30

Wed, 31 Dec 2025 16:01:00 -0500

si-local-file:///var/storage/secattach/20251231/25794398.html

Form EFFECT China SXT Pharmaceutical

Mon, 17 Nov 2025 06:11:00 -0500

si-local-file:///var/storage/secattach/20251117/25621471.html

Form EFFECT China SXT Pharmaceutical

Mon, 17 Nov 2025 06:11:00 -0500

si-local-file:///var/storage/secattach/20251117/25621471.html

Form F-3 China SXT Pharmaceutical

Mon, 10 Nov 2025 17:02:00 -0500

si-local-file:///var/storage/secattach/20251110/25586739.html

Form F-3 China SXT Pharmaceutical

Mon, 10 Nov 2025 17:02:00 -0500

si-local-file:///var/storage/secattach/20251110/25586739.html